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Abstract
Background—Opioid medication to treat acutely injured patients is usual care in trauma 
settings. A higher prevalence of alcohol and other substance misuse in this population compared to 
the general population increases the vulnerability of such patients to both misuse of their 
prescribed opioids, and also unintentional opioid overdose. The primary purpose of this study was 
to assess the prevalence of substance use and unintentional opioid overdose risk among acutely 
injured trauma patients, and to examine the frequency and predictors of high opioid dose at 
discharge.
Methods—A retrospective electronic medical record (EMR) review of three-months of data from 
two Level 1 trauma centers. We assessed the prevalence of substance misuse, unintentional opioid 
overdose risk, and presence of documentation of clinical strategies to mitigate these risks, such as 
co-prescription of the opioid agonist naloxone.
Results—In total, 352 patient EMRs were examined. Over 40% of the patients reviewed had at 
least one indication of substance misuse (42.5% [95%CI: 37.3, 47.7]); at least 1 unintentional 
opioid overdose risk factor was identified in 240 EMR reviewed (68.2% [95%CI: 63.3, 73.1]). 
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Dose of opioid medication was not significantly different for patients with substance misuse 
versus those without. There was no co-prescription of naloxone for any of the discharged patients.
Conclusions—Our results indicate that despite the high rates of substance misuse, the potential 
for misuse, dependence and unintentional overdose risk from prescribed opioid medications are 
prevalent among acutely injured trauma patients. Prescribing after acute trauma care should 
address these risk factors.
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1. Introduction
The United States uses over 80% of all oxycodone manufactured in the world, and more 
than 90% of the world’s manufactured hydrocodone (Manchikanti et al., 2012a), as 
demonstrated by the approximately 250 million prescriptions for opioids dispensed in 2013 
(Centers for Disease Control and Prevention, 2016 Centers for Disease Control and 
Prevention (CDC), 2016). This level of consumption has been linked with unintentional 
opioid related deaths (Centers for Disease Control and Prevention, 2016), which are now at 
epidemic levels (Centers for Disease Control and Prevention, 2011; Manchikanti et al., 
2012b; Volkow and McLellan, 2016), and has led to a discussion to educate both patients 
and physicians about risks that may be associated with medically indicated opioid 
prescriptions (Nelson and Perrone, 2012). The co-ingestion of opioids with psychoactive 
substances, such as alcohol and benzodiazepines, increases the risk of respiratory depression 
and death (Centers for Disease Control and Prevention, 2012; Webster et al., 2011; Dunn et 
al., 2010; Green et al., 2011; Silva et al., 2013). In addition to alcohol and medication use 
risks, there are acute and chronic diseases that have been associated with an increased 
likelihood of overdose, such as chronic obstructive pulmonary diseases, end stage liver and 
renal failure, and congestive heart failure (Webster et al., 2011).
High daily doses of opioids are also associated with increased risk of fatal opioid overdose 
(Dunn et al., 2010). While the definition of “high daily dose” is evolving, many considered 
daily intakes at or exceeding 100 morphine milligram equivalent doses (MME – the metric 
used to quantify the 24-h dose of opioid) as risky (Eder et al., 2005). Naloxone is a 
competitive antagonist (Helm et al., 2008) that binds to opioid receptors, and can reverse the 
effects of an overdose and is considered a key strategy in preventing opioid deaths (Bohnert 
et al., 2011; Walley et al., 2013). There are calls for increasing the availability of naloxone 
through provider opioid co-prescribing and dispensing at community pharmacies and other 
community health care and treatment settings. (Centers for Disease Control and Prevention, 
2015; Davis et al., 2014; Doyon et al., 2014; Green et al., 2015; Green and Doe-Simkins, 
2016). More recent opioid prescribing guidelines for chronic pain issued by the Centers for 
Disease Control and Prevention (CDC, 2016) recommend prescribing naloxone if the daily 
dose of opioids ≥ 50 MME, or when a patient is receiving both benzodiazepines and opioid 
medications, or when there is a patient history of substance use disorder (SUD). The 
maximum daily dose of opioid medication prescribed has been associated with both 
increased risk dependency and unintentional opioid overdose (Cheatle, 2015).
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In the United States, there are annually 2.6 million trauma hospital admissions (Dowell et 
al., 2016), and opioid analgesia therapy is almost ubiquitous among these patients (Wunsch 
et al., 2016). While estimates of substance use vary in the general population from 2% of 
adults who report non-medical use of prescribed drugs to 10.1% who use any illicit drugs 
(Center for Behavioral Health Statistics and Quality, 2016), substance use, and substance 
misuse is much higher among the traumatically injured. Estimates of substance misuse 
among traumatically injured trauma patients has risen to between 40 and 60% (Rosenblatt 
and Mekhail, 2015). Field et al. (2014) reported on the non-medical use of prescription 
opioids for injured at-risk drinkers (defined by authors as an admission for an alcohol relate 
injury, or self-report of heavy drinking) up to 12 months following discharge from a Level 1 
trauma care facility. They found that prior non-medical use of prescribed opioids and/or 
other drug use pre-admission was predictive of using non-prescribed of opioids following 
discharge (Field et al., 2014).
This concomitant concern of high opioid utilization in conjunction with the frequency of 
alcohol and other drug misuse, places injured trauma patients as a population vulnerable to 
the unintended negative consequences of prescription opioids. The challenge, for the health 
care professional, is to adequately control pain without increasing the burden of misuse, 
morbidity, and mortality among those prescribed opioid analgesics. This challenge is more 
difficult in a trauma care setting.
With many trauma patients receiving opioid prescriptions for pain control at discharge, and 
given the known increased misuse of substances among this population, it is critical to 
identify patients at risk for opioid overdose, and to assess the opportunities to introduce 
educational and clinical strategies to reduce those risks associated with prescription opioid 
medication. The purpose of the current study was to describe the frequency of unintentional 
opioid overdose risk among patients admitted to trauma service, and describe demographic 
characteristics associated with those risks. We also wanted to determine if receiving a high 
dose of discharge opioid medication (≥100 MME daily) was predicted by any patients’ 
medical or demographic characteristics, and in particular if the presence of any unintentional 
opioid risk factor moderated the discharge dose.
2. Methods
2.1. Design
This was an observational study using retrospective electronic medical record (EMR) data. 
Patient data and reporting was handled in accordance with the guideline on Strengthening 
and Reporting of Observational Studies in Epidemiology (STROBE) (Noah, 2008).
2.2. Sample
The EMR of patients admitted to Level 1 trauma services at two urban academic hospitals in 
two states were included in the study. Site 1 admits over 2900 trauma patients annually and 
site 2 admits over 1800. Cases were identified using the trauma registry at each site. Criteria 
for inclusion were the admission to and discharge from the trauma services between July 1st 
2014 and September 30th 2014; patient discharged to home; discharged with a prescription 
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for opioid pain medication; and patient age 18 years or older. The data reported on for this 
study were part of a larger study evaluating the effect of a safer opioid prescription protocol 
for discharged trauma patients. These data represent three-months of medical records for 
patients discharged from the trauma services prior to the implementation of the safer opioid 
prescription protocol. The Institutional Review Board at each hospital approved the study 
protocol and provided a waiver of informed patient consent.
2.3. Data extracted
Medical data were extracted from the patients’ EMR for the following main categories of 
data: demographics, admission history, medication, and comorbid medical conditions. The 
content for each of these categories is shown in Fig. 1. The MME dose was calculated for 
the discharge opioid dose by multiplying the frequency of daily dose by the strength of dose 
(or maximum if a range of frequency was recorded). Naloxone prescriptions at discharge 
were recorded. We also recorded if any recorded instruction on safe opioid use (i.e., use as 
prescribed, do not use with alcohol) and safe storage was given to the patient. Most of the 
data was abstracted from the medical record, which included details on the prescribed 
opioids following a discharge.
A classification system for drug types (opioid pain medication, benzodiazepines, other 
sedatives, and non-opioid pain medication) was developed by the research study pharmacist.
2.4. Data extraction protocol and training
The data extraction protocol was developed by the study research investigators, and research 
assistants were trained in the protocol. The explicit EMR data extraction protocol included 
reviewing the same 10 patient charts independently, and discussing with the research team 
any issues of ambiguous or conflicting medical record documentation for any data. The 
research assistants conducting the chart review data abstraction were not blinded to the study 
objectives. Relevant data were extracted from the EMR and entered into a Microsoft Excel 
file at each study site, and later merged into one database. As part of the data extraction 
protocol, 10% of all medical records were reviewed to assess data extraction and rater 
reliability by an independent rater not involved with the initial medical record data 
extraction. When the rater agreement analysis was conducted, data disagreements were 
reviewed by the study investigators at each site, the individual EMR was re-reviewed by the 
research assistant and the investigator, and the corrected entry was included in the analyses.
2.5. Opioid overdose risk factor composite score
Using opioid risk factors identified from the research literature (Dunn et al., 2010; Green et 
al., 2011; Silva et al., 2013; Webster et al., 2011), a composite score for opioid overdose risk 
factors was developed from the EMR data. A score (1 v. 0) was applied to each of the 
following seven risk factors: a.) relevant comorbid medical condition (any one of the 
following: COPD, congestive heart failure, end stage renal or liver disease); b.) home 
opioid/and benzodiazepine medication; c.) discharge benzodiazepine co-prescription; d.) 
discharge opioid medication ≥ 100 MME; e.) positive alcohol or illicit drug screen on 
admission; f.) prior treatment for SUD in past 12 months; g.) opioid overdose in the past 12 
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months. The summed composite score across all seven indicator variables ranged from 0 to 
7.
2.6. Substance use disorder
The substance use disorder (SUD) status of the patient was categorized as: positive as 
identified through trauma service standardized screening, and/or toxicology results 
indicating use of illicit substances or medication not prescribed on admission, and/or prior 
treatment in the past 12 months for substance misuse, and/or opioid overdose in the past 12 
months; or negative if none of these indications were present.
2.7. Data analysis approach
A power analysis was conducted based on the expectation that 30% of the reviewed charts 
would have at least one identified opioid overdose risk factor. We estimated that we would 
have to review a minimum of 322 charts to determine that 30% of charts would have at least 
one indicated risk factor, assuming a 5% error in our estimated proportion.
The data were formatted into Statistical Analysis Software (SAS) (Version 9.2, Carey, NC) 
for statistical analyses. Descriptive data analyses were conducted with means, counts and 
proportions reported with 95% confidence intervals (CIs), and medians with relevant inter-
quartile range (IQR). Comparisons between the two sites were conducted using Wilcoxon 
Signed Ranks test for non-normal continuous data, and a binomial test of proportions and 
Pearson’s Chi-square test for categorical data. The inter-rater reliability of the medical data 
extracted was calculated using Cohen’s Kappa. The coefficient agreement between raters 
was reported for six identified categories: patient demographics, comorbid medical 
conditions, positive toxicology or substance use screen, home medication, discharge 
medications, and discharge opioid medication MME. These agreement rates are reported 
with 95% CIs.
A hierarchical model with log link function (SAS Proc glimmix) was conducted to 
determine the relative risk of opioids overdose risk associated with patient level 
characteristics. The trauma center site was the nesting variable for patients. Based on the 
distribution of opioid overdose risks, the outcome variable was dichotomized into no versus 
at least 1 identified risk factor. Participant predictor variables were gender, race (White, 
African-American/other) ethnicity, age (median centered).
In the second predictive model second model we examined predictors of the discharge dose 
medication strength, dichotomized as < 100MME daily and ≥100MME daily. Patient 
demographic and medical characteristics were entered as predictors. Specifically; any 
medication risk factor (we combined home opioid or benzodiazepine, or discharge co-
prescription of benzodiazepine), SUD status, and co-morbid disorders.
3. Results
3.1. Interrater reliability
During the three-month trauma admission period in which the medical record review data 
were collected, 210 admitted patients were discharged from site one and 261 from site two. 
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Of these patients, 191 (91%) at Site 1 and 160 (62%) from site 2 were discharged to home 
with one or more prescriptions for opioid pain medication, and therefore eligible for study 
inclusion. The initial inter-rater percent agreement was: a. patient descriptive data = 100%; 
b. comorbid medical conditions = 93% (95% CI 89.4, 96.6); c. positive substance use screen 
= 83% (95% CI 77.7, 88.3); d. home medications = 94% (95% CI 90.6, 97.6); e. discharge 
medications = 100%; f. MME > 100 = 89% (95% CI 84.6, 93.4).
3.2. Patient characteristics
Table 1 reports on the demographic characteristics of the included medical record review 
patient sample. Across both sites, most patients were male, White and non-Hispanic. Site 1 
patients were on average older than those at site 2 (43 years versus 32.5 [p < 0.001]), and 
were less likely to be African-American (13.1% versus 46% [p < 0.001]). The average 
length of stay was similar at both sites (site 1 = 4.6 days [95% CI: 3.9, 5.3]; site 2 = 4.4 days 
[95% CI: 3.4, 5.3]).
3.3. Substance use
A toxicology screen for drug use on admission was conducted more frequently in site 1 
(120/191 = 62.8%) compared to site 2 (n = 72/161 = 44.7%). Among those who were tested 
at both sites, 143/192 (74.5%; 95% CI: 68.3, 80.7) screened positive for any substance. 
Table 2 indicates the main drugs detected in the toxicology screens conducted. Opioids were 
the most common positive drug screen, and documentation of prescribed use (i.e., used in 
the trauma care of the patient in the pre-hospital setting, or that the patient was prescribed 
opioids as a home medication), being found for just over half of these patients (53%). 
Among patients who screened positive for drugs on admission; 69.9% were positive for one 
drug, 22.4% for 2 drugs and 7.7% for 3 or 4 drugs. A consult from hospital substance misuse 
services (social work or psychiatric services) was requested for 86 patients. Patients who 
were male, were more likely, if screened, to be positive for alcohol (males = 45.2% [95% CI: 
38.8, 52.0]; females = 22.9% [95% CI: 10.8, 34.1]), but not for other drugs (males = 76.3% 
[95% CI: 69.6, 82.8]; females = 66.7% [95% CI: 52.3, 82.1]). Rates of SUD were calculated 
from the criteria explained in the Methods section. In total 149 participants (42.5% [95%CI: 
37.3, 47.7]) were categorized as having a SUD; the proportion was approximately equal for 
each site.
3.4. Prescribed opioid medications
Oxycodone was the most frequently prescribed opioid at discharge 299/352 (84.9%). 
Typically this was a daily 5 mg dose with 1–2 tablets per dose (n = 258/299, 86.3%); the 
remaining patients had a higher dosage. Across the types of opioid medication prescribed at 
discharge, frequency of dose ranged from 1 to 8 times a day, with the most frequent being 
twice a day (77.6%). The mean days of prescribed dosing was 13.9 days (SD = 8.7) with a 
median of 12 days (IQR = 7.5–16). At discharge, the median discharge 24-h maximum dose 
prescribed was 90 MME, however, high doses of ≥ 100 MME was comparatively common 
in site 1 (39% [95% CI: 25.3, 38.5]), compared to site 2 2.5% [95% CI: 0.88, 4.91]. There 
were no differences in MME of discharge opioid dose for patients who had were classified 
as SUD versus those who did not. Twenty-six patients (7.4%) were co-prescribed a 
benzodiazepine with opioid medication at discharge.
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3.5. Opioid overdose risk factors
Table 3 presents the frequency of risk factors identified from the EMR review. At least 1 
opioid overdose risk factor was identified in 240 patient EMR (68.2% [95% CI: 63.3, 73.1]), 
with a range of 0–5 factors identified. More patients in site 1 (117/191 [61.2%; 95% CI: 
54.4, 68.2]) had identified overdose risk factors than in site 2 (22/161 [13.7%; 95% CI: 8.4, 
19.0]). On admission, home sedating medications and positive drug/alcohol screenings were 
the most commonly identified risk factors.
3.5.1. Predicting opioid overdose risk factors and MME discharge dose—Table 
4 shows the relative risk ratios (with 95% CI s) for an unintentional opioid overdose risk 
from the patient demographic characteristics entered into first model. The known site 
differences between the two Level 1 trauma sites were adjusted for in these hierarchical 
models. In the first model, having a risk factor versus not having one could not be predicted 
by any of the patients’ characteristics. The calculated intraclass correlation (ICC) was 0.24; 
which indicates that 24% of the variability in predicting the overdose risk factors was due to 
trauma site variability. In model 2 we examined the relative risk of being prescribed a high 
potency discharge opioid dose (i.e.≥ 100 MME). Due to low frequency we created a 
medication risk (combination of either benzodiazepine prescribed at discharge, or home 
opioid, or benzodiazepines), SUD status (as described in Methods), and co-morbidity risk, 
and used these composite variables as predictors with the other variables shown in model 2 
on Table 4. No predictor variable was significant in this model. The ICC was 0.28.
3.5.2. Naloxone co-prescription—There were no prescriptions for naloxone given at 
either site for any patients in this record review
4. Discussion
Patients in our study had received prescription opioid medications during their admission 
and were discharged to home with opioid medications to control their pain. Prior research 
has shown that individuals who are prescribed opioids in high doses, with a co-prescription 
of benzodiazepines, or who have a medical comorbidity, or, and substance use disorders 
have an elevated risk of an unintentional opioid overdose (Centers for Disease Control and 
Prevention, 2012; Webster et al., 2011; Dunn et al., 2010; Green et al., 2011; Silva et al., 
2013). These risk factors were identified in over 68% of the trauma patient charts reviewed. 
The presence of these risk factors was not associated with a lower likelihood of having a 
higher potency prescribed daily dose of opioids (≥100 MME) at discharge, and we found no 
individual patient characteristics that were associated with these risks, which would indicate 
that more universal approaches to identifying those are risk for an unintentional opioid 
overdose are needed. We also found that a large variability of prescribing across the two 
sites studied, which is likely due to localized prescribing practices.
There were no documented prevention strategies initiated by clinicians; including no 
prescriptions provided for naloxone for patients who we identified as being at risk for an 
unintentional opioid overdose. Recent clinical guidelines issued by the Centers for Disease 
Control and Prevention (2016), do recommend that prescribers consider co-prescription of 
naloxone when daily doses of opioids exceed 50 MME, or the patient is co-prescribed 
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benzodiazepines. The lack of any naloxone prescribing among the medical records reviewed 
is concerning and suggests that prescribers need to be educated about the unintentional 
opioid overdose risk their patients face, and the role of naloxone in overdose prevention. 
Alternatively, risk factors may have been considered for some patients who were discharged 
from these trauma services without prescribed opioid pain medications (whose data was not 
included in this study); these potential risk factors may have been important in considering 
whether or not to prescribe an opioid analgesic medication.
In conducting the EMR review we found the ease of extracting the indicators of 
unintentional opioid overdose risk varied enormously. Some data were well documented and 
easily retrievable from one or two sources in the EMR, others were not. Data on discharge 
and home medications tended to be contained within easily designated areas in the EMR, 
data on past treatment for SUD was not consistently documented or documented in any one 
section of the EMR. Our sole purpose of the extraction were to find these risk factors, for the 
busy clinician about to discharge a patient, finding these sources of patient medical 
information would require time and effort, which maybe not feasible given the demands of 
clinical care in a trauma setting. The EMR is a powerful tool that could be used to collate 
and highlight important patient medical information that the clinician could use in deciding 
the patient’s discharge medication dose and potential need for naloxone.
Trauma patients may also be a particularly vulnerable group for misusing prescription 
opioids; given the higher SUD rates (Field et al., 2014) than in the general population (Alam 
et al., 2012). Prior research has reported that among trauma patients with a history of risky 
drinking, pre-admission illicit use of prescription opioids and other drugs is predictive of 
long-term opioid use and misuse (King et al., 2014). Comprehensive screening for SUD is 
common in trauma centers, and is required as part of the accreditation process to become a 
Level 1 trauma center. Of the trauma patient’s EMRs we reviewed, over 40% screened 
positive for substance use either by toxicology screen or by a standardized assessment tool, 
and had the potential for SUD. Of these patients, 86 received a consult for their substance 
use. However, the lack of toxicology screens documented in approximately 25% of reviewed 
medical charts does suggest that SUD may be under-reported in this population. Increasing 
screening to identify trauma patients whose substance use history elevates their likelihood of 
misusing their opioid medications, may be another effective strategy to address the crisis we 
currently face of opioid medication misuse, dependency, and overdose. This underscores the 
need for appropriate treatment options, such as medication assisted therapies, as well as 
behavioral counseling.
Central to improving opioid medication safety are multi-level interventions that not only 
target those at high risk, but also primary prevention to promote safer opioid use for all 
patients. Prevention interventions regarding opioid misuse and overdose risk may disrupt the 
continuum of use, risk for misuse, and probability of overdose (Dunn et al., 2010; 
Manchikanti et al., 2012a; Webster et al., 2011). The Food and Drug Administration (FDA) 
has stated that the misuse of prescription opioids can be mitigated in part by educating 
patients about the safe use, storage and disposal of their opioid pain medications (FDA, 
2011). A recent pilot study demonstrated the feasibility and short-term effect of delivering a 
web-based education intervention on the safe use, storage and disposal of prescription opioid 
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pain medications for adult patients attending an outpatient pain management clinic 
(McCauley et al., 2013). There is a growing recognition among clinicians of the importance 
of education to increase patient safety around their prescribed opioid use (American 
Hospital Association, 2016), and to promote the role of naloxone in reducing unintentional 
opioid overdose risk.
As the data gathered here represent patients admitted to only two Level 1 trauma center sites 
in the Northeast of the United States, it may not be generalizable to other trauma center 
sites. There were important differences between the sites that may have accounted for the 
observed difference in frequency and dose of opioids prescribed to trauma patients at 
discharge. Site 1 is the only level 1 trauma center in the region whereas site 2 is one of 
several level 1 trauma centers within the same city; this may result in more severely injured 
patients being admitted at site 1 with a greater corresponding need for opioid medication. 
Across both sites, the EMR was only reviewed for patients who were discharged to home 
with an opioid, so we have no comparative data for patients not discharged to home with 
opioids, whose rate of SUD and opioid overdose risk factors may be as great as what we 
report. Also, discussion about safer opioid medication use, storage and disposal may have 
occurred between patient, nurse, and/or physician, but not recorded.
The Department of Health and Human Services (2015) listed education of providers around 
opioid medication prescription practices and availability of naloxone, as two of three 
national priority areas for reducing opioid abuse and overdose. Our results indicate that there 
are opportunities for engaging with prescribers to inform them of the evidence-based opioid 
overdose risk factors among their acutely injured patients, especially those who may have a 
SUD and receive advanced care at a trauma center.
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Fig. 1. 
Schematic of the extracted electronic medical record review categories and content.
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Table 1
Description of Patients Sample at Two Trauma Center Sites.
Demographic characteristics Site 1 n = 191 Site 2 n = 160
Median age, years (IQR) 43 (31) 32.5 (15)
Range 18–96 18–80
n (%; 95%CI) n (%)
Gender
 Female 43 (22.5; 16.5, 28.4) 32 (20.5; 14.3, 26.7)
 Male 148 (77.5; 71.6, 83.4) 128 (79.5; 76.3, 85.7)
Ethnicity
 Hispanic 22 (11.5; 6.97, 16.0) 25 (16.1; 10.4, 21.8)
 Non-Hispanic 168 (88.0; 83.4, 92.6) 135 (83.9; 78.2, 89.6)
 Not documented 1 (0.52; 0, 1.3) 0
Race
 White 161 (84.3; 79.1, 89.5) 54 (34.2; 26.9, 41.5)
 Black/African-American 25 (13.1; 8.31, 17.9) 74 (46.0; 38.3, 53.7)
 Asian 2 (1.1; 0.0, 2.5) 3 (1.9; 0, 4.01)
 Other 22 (11.5; 7.0, 16.0) 29 (18.0; 12.07, 23.9)
CI = Confidence interval; IQR = inter quartile range.
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Table 2
Screening Test Results for Presence of Alcohol, Prescribed and Illicit Substances on Admission.
Drug Screen Type a
 Positive Screen n (%) b Prescribed n (%)
Opioids 102 (53) 54 (53)
Cannabinoid 45 (23) 2 (4)
Benzodiazepines 30 (16) 13 (43)
Cocaine 29 (15) –
Amphetamines 7 (4) 4 (57)
Barbiturates 3 (2) 3 (100)
Methadone 1 (< 1) 1 (100)
aN = 192 received toxicology screening for drugs.
bOf those with positive toxicology screen for substance.
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Table 3
Identified Opioid Overdose Risk Factors Among the Trauma Patients.
Risk Factors N = 351 n (%; 95%CI)
Co-morbidity
 Respiratory Disease 21 (6.0; 3.5, 8.4)
 Renal Disease 4 (1.1; 0.0, 2.2)
 Cardiac Disease 7 (2.0; 0.6, 3.4)
 Liver Disease 14 (4.0; 1.9, 6.0)
Medication
 Home
  Rx opioid home 29 (8.2; 5.4, 11.1)
  Rx benzodiazepine home 6 (1.7; 0.40, 3.1)
 Discharge
  Rx benzodiazepine 26 (7.4; 4.7, 10.1)
  Rx opioid dose > 100 MME 61 (31.9; 27, 36.8)
Admission Substance Screen
 Alcohol Positive 110 (31.3; 26.5, 35.1)
 Alcohol Negative 157 (44.7; 39.5, 50.2)
 Alcohol Not Documented 85 (24.2; 19.7, 28.7)
 Drug Positive 143 (40.7; 35.6, 45.8)
 Drug Negative 49 (14.0; 11.6, 17.6)
 Drug Not documented 160 (45.6; 40.4; 50.7)
Substance Misuse
 Tx alcohol/substance abuse (last 12 months) 12 (3.4; 1.5, 5.3)
 Prior opioid overdose (last 12 months) 3 (< 1)
Tx = treatment; Rx = Prescription; MME = Morphine Milligram Equivalent; CI = Confidence interval.
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Table 4
Hierarchical Regression Models Predicting Relative risk for Opioid Overdose Risk Opioid Risk Factors and 
Opioid Prescribed Discharge Dose ≥ 100 MME.
Model 1 Identified Opioid Overdose Risk Factor
Predictors RR 95%CI
Gender (Female = referent) 1.23 0.07, 19.9
Race (White = referent) 0.60 0.02, 17.5
Ethnicity (Hispanic = referent) 1.21 0.30, 57.1
Age (median = 36) 1.30 0.11, 15.1
Model 2 Discharge Opioid Medication Daily Dose ≥ 100 MME
Predictors RR 95%CI
Gender (Female = referent) 0.74 0.02, 44.7
Race (White = referent) 1.90 0.003, > 100
Ethnicity (non-Hispanic = referent) 0.66 0.001, > 100
Age (median = 36) 0.87 0.04, 18.4
Medication risk factor (0 = referent) 0.65 0.02, 20.1
Substance use disorder risk (0 = referent) 0.79 0.004, 13.92
Medical comorbidity (0 = referent) 1.83 0.004, > 100
MME = Morphine Milligram Equivalent; RR = Relative risk ratios; CI = confidence intervals.
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